Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97053533 | 9705353 | 3 | F | 20160720 | 20131122 | 20160720 | EXP | IT-BRISTOL-MYERS SQUIBB COMPANY-19838689 | BRISTOL MYERS SQUIBB | 0.00 | Y | 0.00000 | 20160720 | CN | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97053533 | 9705353 | 1 | PS | STAVUDINE. | STAVUDINE | 1 | Transplacental | U | 20412 | ||||||||||
| 97053533 | 9705353 | 2 | SS | LAMIVUDINE. | LAMIVUDINE | 1 | Transplacental | U | 0 | ||||||||||
| 97053533 | 9705353 | 3 | SS | NELFINAVIR | NELFINAVIR | 1 | Transplacental | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 97053533 | 9705353 | 1 | Product used for unknown indication |
| 97053533 | 9705353 | 2 | Product used for unknown indication |
| 97053533 | 9705353 | 3 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 97053533 | 9705353 | OT |
| 97053533 | 9705353 | CA |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 97053533 | 9705353 | Foetal exposure during pregnancy | |
| 97053533 | 9705353 | Patent ductus arteriosus |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |